{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:37:44Z","timestamp":1792802264114,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06878-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:08:32Z","timestamp":1792757312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical response outweighs baseline nodal stage in treatment selection and survival of clinically node-positive bladder cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"L. F.","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"van Gennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"6878_CR1","unstructured":"European Association of Urology (2025) EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Retrieved from https:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/"},{"issue":"1","key":"6878_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","volume":"118","author":"K Br\u00fcck","year":"2024","unstructured":"Br\u00fcck K, Meijer RP, Boormans JL, Kiemeney LA, Witjes JA, van Hoogstraten LMC et al (2024) Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys 118(1):41\u201349. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"6878_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24(6):669\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"6878_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.urology.2020.06.091","volume":"146","author":"C Darwish","year":"2020","unstructured":"Darwish C, Sparks A, Amdur R, Reddy A, Whalen M (2020) Trends in treatment strategies and comparison of outcomes in lymph node positive bladder cancer: an analysis of the National Cancer Database. Urology 146:168\u201376. https:\/\/doi.org\/10.1016\/j.urology.2020.06.091","journal-title":"Urology"},{"issue":"4","key":"6878_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2026.01.013","volume":"89","author":"R Pichler","year":"2026","unstructured":"Pichler R, Subiela JD, Scilipoti P, Rehder P, Grivas P (2026) Regional node\u2013positive bladder cancer: therapeutic decisions based on trial results in perioperative and advanced disease settings. Eur Urol 89(4):302\u2013304. https:\/\/doi.org\/10.1016\/j.eururo.2026.01.013","journal-title":"Eur Urol"},{"issue":"19","key":"6878_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/nejmoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M et al (2023) Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 389(19):1778\u20131789. https:\/\/doi.org\/10.1056\/nejmoa2309863","journal-title":"N Engl J Med"},{"issue":"10","key":"6878_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/nejmoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J et al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/nejmoa2312117","journal-title":"N Engl J Med"},{"issue":"4","key":"6878_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ejso.2013.01.003","volume":"39","author":"RP Meijer","year":"2013","unstructured":"Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, Van Der Poel HG, Van Rhijn BW et al (2013) Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience. Eur J Surg Oncol 39(4):365\u2013371. https:\/\/doi.org\/10.1016\/j.ejso.2013.01.003","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6878_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urology.2013.08.082","volume":"83","author":"RP Meijer","year":"2014","unstructured":"Meijer RP, Mertens LS, Van Rhijn BW, Bex A, Van Der Poel HG, Meinhardt W et al (2014) Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 83(1):134\u20139. https:\/\/doi.org\/10.1016\/j.urology.2013.08.082","journal-title":"Urology"},{"key":"6878_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.015","volume":"69","author":"TJN Hermans","year":"2016","unstructured":"Hermans TJN, van de Fransen EE, Horenblas S, Meijer RP, Boormans JL, Aben KKH et al (2016) Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer\u2014Results of a nationwide population-based study. Eur J Cancer 69:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.015","journal-title":"Eur J Cancer"},{"issue":"1","key":"6878_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2015.07.085","volume":"195","author":"K Zargar-Shoshtari","year":"2016","unstructured":"Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, Van Rhijn BW, Daneshmand S et al (2016) A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol 195(1):53\u20139. https:\/\/doi.org\/10.1016\/j.juro.2015.07.085","journal-title":"J Urol"},{"issue":"2","key":"6878_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.urolonc.2015.08.012","volume":"34","author":"PL Ho","year":"2016","unstructured":"Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ et al (2016) Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urologic Oncology: Seminars Original Investigations 34(2):59. https:\/\/doi.org\/10.1016\/j.urolonc.2015.08.012","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"6878_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00725","author":"M Swinton","year":"2023","unstructured":"Swinton M, Mariam NBG, Tan JL, Murphy K, Elumalai T, Soni M et al (2023) Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.23.00725","journal-title":"J Clin Oncol"},{"issue":"3","key":"6878_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bju.16210","volume":"133","author":"M von Deimling","year":"2024","unstructured":"von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M et al (2024) Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. BJU Int 133(3):341\u201350. https:\/\/doi.org\/10.1111\/bju.16210","journal-title":"BJU Int"},{"issue":"4","key":"6878_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2025.04.019","volume":"88","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, van der Heijden MS, Powles T, Claps M, Burotto M, Schenker M et al (2025) Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. Eur Urol 88(4):325\u2013330. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.019","journal-title":"Eur Urol"},{"key":"6878_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70403","author":"R Contieri","year":"2026","unstructured":"Contieri R, van Rhijn BWG, Cathomas R, Lorch A, Oprea-Lager D, Mariappan P et al (2026) Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice. BJU Int. https:\/\/doi.org\/10.1111\/bju.70403","journal-title":"BJU Int"},{"issue":"13","key":"6878_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke C, Adra N, Danchaivijitr P et al (2026) Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N Engl J Med 394(13):1257\u20131269","journal-title":"N Engl J Med"},{"key":"6878_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa2601486","volume":"395","author":"MD Galsky","year":"2026","unstructured":"Galsky MD, Valderrama BP, Maruzzo M et al (2026) Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 395:338\u2013348","journal-title":"N Engl J Med"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06878-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:01:58Z","timestamp":1792800118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06878-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6878"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06878-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"30 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review boards (protocol IRBd20-047) of all centres and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the same institutional review boards (protocol IRBd20-047) due to the retrospective design of the study, in accordance with institutional guidelines and applicable national regulations.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"759"}}